



Date: 31 January 2023

Quarterly Operations Review

ASX Announcement

ABN 11 124 426 339

Level 3, 2-4 Ross Place, South
Melbourne, VIC 3205

P: +61 (3) 9673 9690

E: corporate@purifloh.com

www.purifloh.com

Operation Report for Quarter Ended 31 December 2022

The Company continued its product Research and Development based out of Victoria and under the management of Vigneswaran Appia, as follows:

R&D and Independent testing

The evolution of the FRG into a “zero-ozone” version during the quarter is a significant achievement. While the company continues commercializing its previous versions of air purifiers, effective against most contaminants, the zero-ozone version removes any need for expensive and large neutralizer filters while maintaining anti-microbial efficacy. The zero ozone device can act as a booster to the effectiveness of any air purifier. Internal testing has shown that, when combined with a standard HEPA-filter based air purifier, the zero-ozone FRG version can improve its rate of removal of microbes by 150% - 170%. Purifloh is working towards providing independently verified results of this unique product which will be an important part of OEM integration efforts.

The company continues its validation of the ACERT technology against mould spores and is similarly conducting internal tests and seeking independent validation.

Independent results on both activities above will be reported as they become available.

The company has also restarted R&D efforts in the medical grade sterilization arena and is pursuing new IP in this high-potential market.

Partnerships and commercialization:

The company has received positive feedback from Osmoflo after nearly one year of testing and looks forward to providing further information on this development in the near future.

The company continues to seek other strategic partnerships for installation and maintenance of the ACERT and Air Purifier products together with partnership options on manufacturing and distribution. The company is also continuing with ongoing design activities on both of these products.

Comment on Appendix 4C – Quarterly Cashflow Report

- The Company notes that it has continued to operate on funds drawn down from its Dilato facility.
- The Company drew down an additional \$75,000 during the quarter and retains a facility through Dilato of \$2.275M. Dilato has confirmed with the Company that the facility remains available.
- Funds spent during the quarter were mainly on corporate costs and fees for parties working on R&D activities within the Company.
- Director fees continue to be accrued.

This ASX announcement was authorized and approved by the Chairman of Purifloh Limited.

End

For further information:

**Carl Le Souef (Director)
Melbourne, Australia
+ 613 9673 9673**

For personal use only